To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

Cost and committee reports

Official records Congress.gov attaches to H.R. 1051.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Ms. BUDZINSKI, as printed in the Congressional Record (Vol. 171, No. 25, February 6, 2025, Page H556):
  Article 1 Section 8
  Source: Congress.gov, Congressional Record February 6, 2025 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  19 characters

  Congress.gov bill record

  H.R. 1051, 119th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/119/hr/1051

  Record last updated by Congress.gov

  June 9, 2025

  PORKER copy retrieved

  September 13, 2026

  Stored copy, SHA-256 of the file

  61a9fbf9e8d5fe9599576babb9479e0e06bb1580942a3db2bc93a33562fe4ed4

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of June 9, 2025). Not every bill gets one.

From the Congress.gov bill record for H.R. 1051, last updated June 9, 2025. PORKER’s copy was retrieved September 13, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.